Doctor Abandons US Patent Application
By Solomon Times,
Solomon Times
| 04. 11. 2011
The patent application was launched by US based lawyers on behalf of Taiwanese scientist, Dr Ko Ying-Chin.
According to the US Patent Application Information Retrieval system, US based lawyers representing Taiwanese scientist, Dr Ko Ying-Chin, have since filed an express abandonment application on the first of this month for the patent application number.
NIPS says the express abandonment was subsequently processed by the US body on Monday this week and now the status of the US patent application is listed as "expressly abandoned.
Effectively, the patent application is now stopped.
This patent application entitled "Method and Kit for Assessing Risk of Gout and Hyperuricemia," uses samples from 192 Solomon Islanders, collected at the National Referral Hospital and two clinics in Guadalcanal Province during a research trip led by Dr Ko in September 2006.
Dr Ko and his colleagues only abandoned the patent application after NIPS, along with other non-governmental organizations in the Solomon Islands, began to publicly challenge it.
The basis of this challenge was Dr Ko's failure to obtain proper informed consent from the blood donors for such commercialization.
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...